Where to Buy Sermorelin: Per mg, Per Fill, Per Month

The pharmacy column on this table is the unusual one. For most compounds in this category it is theoretical, because no approval ever existed to compound from. Here it is real, and the section after next explains the mechanism.

Read the last column first. It is the only one where the four channels differ by a category rather than by a degree, and it is the one that decides whether the price you are quoted describes anything.

This site converts everything to a rate. On this question the conversion works for one channel and fails for three, and the failure is informative rather than an inconvenience.

The bottom two rows are blank on purpose. A monthly programme fee usually covers an evaluation, the prescriber's time, laboratory work and the preparation itself, and none of those are milligrams. Dividing a bundled fee by a mass nobody published produces a number that looks rigorous and means nothing.

So the comparison people want, a research vial against a clinic programme, is not a price comparison at all. It is a comparison between buying a quantity of powder and buying a service that includes a quantity of preparation. Our price page runs every division that can honestly be run on the one channel that publishes both numbers.

Sermorelin was an approved drug. EMD Serono marketed it as Geref under two applications: NDA 019863, a diagnostic presentation of 0.05 mg per ampoule with submissions from 1991, and NDA 020443, a therapeutic presentation of 0.5 mg and 1 mg per vial approved on 1997-09-26. Both now carry a marketing status of Discontinued, and the FDA product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. There is no current US label and DailyMed returns none.

Under section 503A a compounding pharmacy may work from a bulk substance that is a component of an FDA-approved drug product, even where no monograph exists. Sermorelin acetate was a component of exactly that, which is why the pharmacy column on the first table is populated rather than hypothetical.

The contrast makes it concrete. FDA maintains a Category 2 list of bulk substances that may present significant safety risks. Ibutamoren mesylate sits on it under both 503A and 503B. Ipamorelin acetate sits on it, as do GHRP-2 and GHRP-6, and kisspeptin-10 appears under 503A. Several others, including BPC-157, Melanotan II and epitalon, were nominated and then withdrawn. Sermorelin does not appear on the Category 2 list at all, and that is the structural difference between it and almost everything sold beside it. Our prescription route page covers what a prescriber will actually ask for.

A legitimate route is not a body of evidence, and conflating the two is the most common error on this topic in both directions.

The approvals that existed covered paediatric growth hormone deficiency and pituitary diagnostics. The market that exists today sells adult vitality, sleep and body composition. Those are different propositions, and the literature is unambiguous about which one it covers. PubMed returns 332 records mentioning the compound, 3 with it in the title, and 29 tagged as clinical trials. Search it alongside anti-aging and the count is zero. ClinicalTrials.gov registers no studies naming it at all, so any page citing a trial identifier for this compound is citing something that does not exist.

The three papers with the term in the title are a 2006 review in Clinical Interventions in Aging on adult-onset growth hormone insufficiency (PMID 18046908), a 1999 BioDrugs review of use in diagnosis and treatment of children with idiopathic growth hormone deficiency (PMID 18031173), and a 2021 paper in Annals of Translational Medicine concerning recurrent glioma (PMID 33842627) which has nothing to do with any buyer question.

A prescriber operating inside the 503A route is doing something lawful. That says nothing about outcome, and no honest page can supply the missing evidence by pointing at the regulation.

Overseas listings usually undercut domestic ones on the vial price, and the undercut is real. What it buys is a longer chain with fewer checkpoints.

• Transit time. A lyophilised powder is more forgiving than a solution, but every extra week is a week in unknown conditions. Our storage guide covers what the dry form tolerates.
• Recourse. A domestic refund policy is enforceable in a way a foreign one usually is not. Recourse has no price on a listing and a very high price when you need it.
• Lot documentation. The check that matters most is whether a certificate exists for the specific lot in your box. A generic document, or one with no lot code, describes someone else's material.
• Customs. A parcel that does not arrive converts the cheapest price per milligram into an infinite one, since the denominator is zero.

That last point is the arithmetic version of the argument. A rate is only a rate if the mass arrives. Running the numbers on a vial that clears customs 80 % of the time means multiplying the price by 1.25 before comparing it, and nobody publishes the figure that would make that calculation honest.

The decision is not really about price, so a price-led decision usually ends badly. Three questions settle it faster.

Do you need a person in the loop? If the answer is yes, the research vial is the wrong channel regardless of its rate, because it comes with no evaluation, no monitoring and no clinician. Our local-intent page covers what a clinic visit involves.

Do you need a document you can check? The research listing publishes a batch certificate before you pay. Lot 38-01260229 reports 99.79 % purity by HPLC-UV-MS across 4 detected peaks and a measured quantity of 11.31 mg against a 10 mg label, analysed at MZ Biolabs on 2026-02-07. It reports no endotoxin test and no sterility test, and that scope belongs to the lot rather than the vendor.

Are you comparing rates or bundles? $3.18 per milligram is a rate. A monthly clinic fee is a bundle. Putting them in the same sentence with a "versus" between them is the single most misleading thing a page in this category does, and it is usually done by the pages that want the vial to win.